Koristi cjepiva protiv covida-19 AstraZenece premašuju moguće rizike i zemlje diljem Europe bi ga trebale nastaviti koristiti kako bi spasili živote, poručio je u četvrtak direktor ogranka Svjetske zdravstvene organizacije (WHO) za Europu.
Hans Kluge je kazao da europska medicinska regulatorna tijela istražuju manji broj slučajeva stvaranja krvnih ugrušaka u nekim europskim zemljama, zbog čega je više članica EU-a privremeno prekinulo upotrebu cjepiva spomenutog proizvođača.
Važna obavijest:
Sukladno članku 94. Zakona o elektroničkim medijima, komentiranje članaka na web portalu Poslovni.hr dopušteno je samo registriranim korisnicima. Svaki korisnik koji želi komentirati članke obvezan je prethodno se upoznati s Pravilima komentiranja na web portalu Poslovni.hr te sa zabranama propisanim stavkom 2. članka 94. Zakona.“The cause of our patients’ condition has now been found,” Pal Andre Holme, the head of a research group at the Oslo University Hospital, told Norway’s VG media outlet. He was referring to the cases of three health workers under the age of 50 who suffered from severe blood clotting after receiving the AstraZeneca jab. One of the medics then died on Monday.
The clotting in those patients was triggered by a very specific “strong immune response” likely caused as a result of the AstraZeneca jab, Holme explained. In collaboration with the University Hospital of North Norway, Holme’s team detected specific antibodies that “activate” platelets and in some cases can lead to blood clots.
Asked by VG if the vaccine was the “most likely” cause of this specific immune response, Holme said he believes “there is no other thing” in the history of the three individual patients which would generate such a response. None of the three patients had a history of similar health issues before, he said. “
Uključite se u raspravu